IL6 and neoplasm: Inhibition of IL-6/JAK/STAT3 signaling can also affect the tumor microenvironment and has implications for antitumor immunity; therefore, determining whether co-targeting of immune checkpoints and the IL-6/JAK/STAT3 signaling pathway mightbe beneficial is important [14].